RFCA
PDLI

R&F Capital Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

R&F Capital Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,213
Closed -$32K – 905
2016
Q4 		$32K Buy
+15,213
New +$42.4K 0.01% 481

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

R&F Capital Advisors's PDLI Position: Q1 2017 in Review

R&F Capital Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2017, closing a stake of 15,213 shares — an estimated $32K sold.

R&F Capital Advisors first reported a position in PDLI in Q4 2016 and held it in 1 quarter. The position peaked at $32K in Q4 2016. 174 funds tracked by Wall St. Rank hold PDLI as of Q1 2017.

  • R&F Capital Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 15,213 PDL BioPharma, Inc. shares in Q1 2017, an estimated $32K.
  • R&F Capital Advisors first reported a position in PDL BioPharma, Inc. in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's PDL BioPharma, Inc. position peaked at $32K in Q4 2016.
  • 174 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.